Vectura Group Interim Results for H1 2018
Chippenham, UK - 11 September 2018: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces its unaudited Interim Results for the six months ended 30 June 2018 and reiterates its current guidance for the full year.
For full details, please click here.
Commenting on the results, James Ward-Lilley, Chief Executive Officer of Vectura, said: "Vectura is regaining momentum after a challenging 2017. Inhaled in-market growth is continuing with flutiform® stock levels normalising resulting in total inhaled Vectura revenues increasing 7.1% vs H1 2017.
"Our refocussed pipeline is making progress with Phase II VR647 results a key highlight in H1 2018. We have identified and are progressing a series of new pipeline projects, and we look forward to the read-out of the VR475 Phase III adult asthma study later this year.
"With positive in-market momentum and additional pipeline catalysts, we look forward to delivering against our strategy in the second half of 2018 and we maintain our full-year guidance."